nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2021-8-4-60-70nodgo-773Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSГенетические основы клинических вариантов токсичности химиотерапии у детей с острым лимфобластным лейкозом (обзор литературы)Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review)https://orcid.org/0000-0002-0050-0721ГурьеваО. Д.GurievaO. D.

О.Д. Гурьева: врач-детский онколог отделения детской онкологии и гематологии (химиотерапия гемобластозов) № 1 НИИ детской онкологии и гематологии НМИЦ онкологии им. Н.Н. Блохина

115478, Москва, Каширское шоссе, 23125993, Москва, ул. Баррикадная, 2/1, стр. 1

O.D. Gurieva: Pediatric Oncologist Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 1 of the Research Institute of Pediatric Oncology and Hematology at N.N. Blokhin National Medical Research Center of Oncology

115478, Moscow, Kashirskoe Shosse, 23125993, Moscow, Barrikadnaya St., Bld. 1, 2/1

swimmer96ok@gmail.comhttps://orcid.org/0000-0002-2373-2250СавельеваМ. И.SavelyevaM. I.

М.И. Савельева: д.м.н., профессор кафедры клинической фармакологии и терапии им. акад. Б.Е. Вотчала

125993, Москва, ул. Баррикадная, 2/1, стр. 1

M.I. Savelyeva: Dr. of Sci. (Med.), Professor at the Department of Clinical Pharmacology and Therapy named after Academician B.E. Votchal

125993, Moscow, Barrikadnaya St., Bld. 1, 2/1

marinasavelyeva@mail.ruhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievT. T.

Т.Т. Валиев: д.м.н., заведующий отделением детской онкологии и гематологии (химиотерапия гемобластозов) № 1 НИИ детской онкологии и гематологии НМИЦ онкологии им. Н.Н. Блохина, профессор кафедры детской онкологии им. акад. Л.А. Дурнова РМАНПО

115478, Москва, Каширское шоссе, 23125993, Москва, ул. Баррикадная, 2/1, стр. 1

T.T. Valiev: Dr. of Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 1 of the Research Institute of Pediatric Oncology and Hematology at N.N. Blokhin National Medical Research Center of Oncology; Professor at the Department of Pediatric Oncology named after Academician L.A. Durnov at Russian Medical Academy of Continuing Professional Education

115478, Moscow, Kashirskoe Shosse, 23125993, Moscow, Barrikadnaya St., Bld. 1, 2/1

timurvaliev@mail.ruФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России; ФГБОУ ДПО РМАНПО Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education, Ministry of Health of RussiaRussian FederationФГБОУ ДПО РМАНПО Минздрава РоссииРоссияRussian Medical Academy of Continuous Professional Education, Ministry of Health of RussiaRussian Federation202120012022846070Copyright © Гурьева О.Д., Савельева М.И., Валиев Т.Т., 20222022Гурьева О.Д., Савельева М.И., Валиев Т.Т.Gurieva O.D., Savelyeva M.I., Valiev T.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/773

Несмотря на значительные успехи в лечении и высокие показатели излечения острого лимфобластного лейкоза (ОЛЛ) у детей, пациенты все еще страдают от многочисленных нежелательных лекарственных реакций, иногда требующих снижения дозы или даже прекращения приема цитотоксических препаратов с вторичным риском рецидива заболевания. Кроме того, исследователи отмечают значительную межиндивидуальную вариабельность лекарственной токсичности и исходов заболевания, что обусловливает роль фармакогенетики (ФГ) в выявлении генетических полиморфизмов в генах-кандидатах для оптимизации лечения заболевания. По всему миру проводятся исследования, направленные на анализ корреляций между генетическими полиморфизмами и проявлениями токсичности в различных этнических группах больных. В России подобные исследования крайне редки. В данной обзорной статье мы приводим аннотации генов-кандидатов лекарств с наивысшей степенью доказательности их роли в проявлении различных клинических вариантов токсичности и предложения по дальнейшему внедрению ФГ для индивидуализации протоколов лечения детей с ОЛЛ

Inspite of great successes in treatment and high incidence of surveillance in pediatric acute lymphoblastic leukemia (ALL), patients are addicted to many drugs adverse events, which sometimes indicate to decrease the dose or even cytotoxic drug interruption with following risk of secondary disease relapse. Besides, researches found significant inter-individual variability of drugs toxicity and disease outcome. This fact specify a role of pharmacogenetics (PGx) in genetic polymorphism revealing in gene-candidates for treatment optimization. Global wide initiated studies of correlation analysis between genetic polymorphism and toxicity effects of ALL treatment in different ethnic groups of patients. In Russia such studies are rare.In the current review we present annotations of gene-candidates of drugs with highest degree of proof their role in different types of clinical toxicity variants and recommendations for following PGx use in individualization of treatment protocols for pediatric ALL.

фармакогенетикалекарственная токсичностьцитостатикихимиотерапияострый лимфобластный лейкоздетиpharmacogeneticdrug toxicitycytostaticschemotherapyacute lymphoblastic leukemiachildrenReferencesEvans W.E., Crews K.R., Pui C.H. A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther. 2013;94(2):224–9. doi:10.1038/clpt.2013.9.Evans W.E., Crews K.R., Pui C.H. A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther. 2013;94(2):224–9. doi:10.1038/clpt.2013.9.Pavlovic S., Kotur N., Stankovic B., Zukic B., Gasic V., Dokmanovic L. Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: paving the Way to Personalized Treatment. Genes. 2019;10(3):3. doi:10.3390/genes10030191.Pavlovic S., Kotur N., Stankovic B., Zukic B., Gasic V., Dokmanovic L. Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: paving the Way to Personalized Treatment. Genes. 2019;10(3):3. doi:10.3390/genes10030191.Chabner B.A., Longo D.L. Cancer chemotherapy, immunotherapy and biotherapy: Principles and practice, 6th edition. Philadelphia: Wolters Kluwer, 2019. Pp. 49–68.Chabner B.A., Longo D.L. Cancer chemotherapy, immunotherapy and biotherapy: Principles and practice, 6th edition. Philadelphia: Wolters Kluwer, 2019. Pp. 49–68.GWAS и психогенетика: консорциумы в поисках ассоциаций. [Электронный ресурс]: https://biomolecula.ru/articles/gwas-ipsikhogenetika-konsortsiumy-v-poiskakh-assotsiatsii (дата обращения 07.12.2021).GWAS and psychogenetics: consortia in search of associations. [Electronic resource]: https://biomolecula.ru/articles/gwas-i-psikhogenetika-konsortsiumy-v-poiskakh-assotsiatsii (appeal date 07.12.2021). (In Russ.).Pearson T.A., Manolio T.A. How to interpret a genome-wide association study. JAMA. 2008;299(11):1335–44. doi:10.1001/jama.299.11.1335.Pearson T.A., Manolio T.A. How to interpret a genome-wide association study. JAMA. 2008;299(11):1335–44. doi:10.1001/jama.299.11.1335.Lopez-Lopez E., Gutierrez-Camino A., Bilbao-Aldaiturriaga N., Pombar-Gomez M., Martin-Guerrero I., Garcia-Orad A. Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(10):1383–98. doi:10.2217/pgs.14.1064.Lopez-Lopez E., Gutierrez-Camino A., Bilbao-Aldaiturriaga N., Pombar-Gomez M., Martin-Guerrero I., Garcia-Orad A. Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(10):1383–98. doi:10.2217/pgs.14.1064.Al-Mahayri Z.N., Patrinos G.P., Ali B.R. Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations. Pharmacogenomics. 2017;18(7):687–99. doi:10.2217/pgs-2017-0005.Al-Mahayri Z.N., Patrinos G.P., Ali B.R. Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations. Pharmacogenomics. 2017;18(7):687–99. doi:10.2217/pgs-2017-0005.Lee S.H.R., Yang J.J. Pharmacogenomics in acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2017;30(3):229–36. doi:10.1016/j.beha.2017.07.007.Lee S.H.R., Yang J.J. Pharmacogenomics in acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2017;30(3):229–36. doi:10.1016/j.beha.2017.07.007.Mei L., Ontiveros E.P., Griffiths E.A., Thompson J.E., Wang E.S., Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev. 2015;29(4):243–9. doi:10.1016/j.blre.2015.01.001.Mei L., Ontiveros E.P., Griffiths E.A., Thompson J.E., Wang E.S., Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev. 2015;29(4):243–9. doi:10.1016/j.blre.2015.01.001.Rudin S., Marable M., Huang R.S. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics. 2017;15(2):82–93. doi:10.1016/j.gpb.2016.11.003.Rudin S., Marable M., Huang R.S. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics. 2017;15(2):82–93. doi:10.1016/j.gpb.2016.11.003.Schmiegelow K., Nielsen S.N., Frandsen T.L., Nersting J. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36(7):503–17. doi:10.1097/MPH.0000000000000206.Schmiegelow K., Nielsen S.N., Frandsen T.L., Nersting J. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36(7):503–17. doi:10.1097/MPH.0000000000000206.Davidsen M.L., Dalhoff K., Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30(11):831–49. doi:10.1097/MPH.0b013e3181868570.Davidsen M.L., Dalhoff K., Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30(11):831–49. doi:10.1097/MPH.0b013e3181868570.Maxwell R.R., Cole P.D. Pharmacogenetic predictors of treatmentrelated toxicity among children with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12(3):176–86. doi:10.1007/s11899-017-0376-z.Maxwell R.R., Cole P.D. Pharmacogenetic predictors of treatmentrelated toxicity among children with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12(3):176–86. doi:10.1007/s11899-017-0376-z.Relling M.V., Ramsey L.B. Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. Hematology Am Soc Hematol Educ Program. 2013;2013(1):126–30. doi:10.1182/asheducation-2013.1.126.Relling M.V., Ramsey L.B. Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. Hematology Am Soc Hematol Educ Program. 2013;2013(1):126–30. doi:10.1182/asheducation-2013.1.126.Zaza G., Cheok M., Krynetskaia N., Thorn C., Stocco G., Hebert J.M., McLeod H., Weinshilboum R.M., Relling M.V., Evans W.E., Klein T.E., Altman R.B. Thiopurine pathway. Pharmacogenet Genomics. 2010;20(9):573–4. doi:10.1097/FPC.0b013e328334338f13.Zaza G., Cheok M., Krynetskaia N., Thorn C., Stocco G., Hebert J.M., McLeod H., Weinshilboum R.M., Relling M.V., Evans W.E., Klein T.E., Altman R.B. Thiopurine pathway. Pharmacogenet Genomics. 2010;20(9):573–4. doi:10.1097/FPC.0b013e328334338f13.Mikkelsen T.S., Thorn C.F., Yang J.J., Ulrich C.M., French D., Zaza G., Dunnenberger H.M., Marsh S., McLeod H.L., Giacomini K., Becker M.L., Gaedigk R., Leeder J.S., Kager L., Relling M.V., Evans W., Klein T.E., Altman R.B. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011;21(10):679–86. doi:10.1097/FPC.0b013e328343dd93.Mikkelsen T.S., Thorn C.F., Yang J.J., Ulrich C.M., French D., Zaza G., Dunnenberger H.M., Marsh S., McLeod H.L., Giacomini K., Becker M.L., Gaedigk R., Leeder J.S., Kager L., Relling M.V., Evans W., Klein T.E., Altman R.B. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011;21(10):679–86. doi:10.1097/FPC.0b013e328343dd93.Gregers J., Gréen H., Christensen I.J., Dalhoff K., Schroeder H., Carlsen N., Rosthoej S., Lausen B., Schmiegelow K., Peterson C. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(4):372–9. doi:10.1038/tpj.2014.81.Gregers J., Gréen H., Christensen I.J., Dalhoff K., Schroeder H., Carlsen N., Rosthoej S., Lausen B., Schmiegelow K., Peterson C. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(4):372–9. doi:10.1038/tpj.2014.81.Zgheib N.K., Akra-Ismail M., Aridi C., Mahfouz R., Abboud M.R., Solh H., Muwakkit S.A. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2014;24(8):387–96. doi:10.1097/FPC.0000000000000069.Zgheib N.K., Akra-Ismail M., Aridi C., Mahfouz R., Abboud M.R., Solh H., Muwakkit S.A. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2014;24(8):387–96. doi:10.1097/FPC.0000000000000069.El Fayoumi R.I., Hagras M.M., Abozenadaha A., Gari M., Abosoudah I., Shinawi T., Mirza T., Bawazir W. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia. Pharmacol Rep. 2019;71(1):90–5. doi:10.1016/j.pharep.2018.09.010.El Fayoumi R.I., Hagras M.M., Abozenadaha A., Gari M., Abosoudah I., Shinawi T., Mirza T., Bawazir W. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia. Pharmacol Rep. 2019;71(1):90–5. doi:10.1016/j.pharep.2018.09.010.Liu Y., Yi Y., Sheng Q., Xiaotong W., Fang L., Zhiyan T., Huaiping X., Ajing Z. Association of ABCC2 −24C>T Polymorphism with HighDose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia. PLoS One. 2014;9(3):e91384. doi:10.1371/journal.pone.0091384.Liu Y., Yi Y., Sheng Q., Xiaotong W., Fang L., Zhiyan T., Huaiping X., Ajing Z. Association of ABCC2 −24C>T Polymorphism with HighDose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia. PLoS One. 2014;9(3):e91384. doi:10.1371/journal.pone.0091384.Hareedy M.S., El Desoky E.S., Woillard J.B., Thabet R.H., Ali A.M., Marquet P., Picard N. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015;16(10):1119–34. doi:10.2217/PGS.15.62.Hareedy M.S., El Desoky E.S., Woillard J.B., Thabet R.H., Ali A.M., Marquet P., Picard N. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015;16(10):1119–34. doi:10.2217/PGS.15.62.Tanaka Y., Nakadate H., Kondoh K., Nakamura K., Koh K., Manabe A. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2018;18(2):275–80. doi:10.1038/tpj.2017.12.Tanaka Y., Nakadate H., Kondoh K., Nakamura K., Koh K., Manabe A. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2018;18(2):275–80. doi:10.1038/tpj.2017.12.Gregers J., Christensen I.J., Dalhoff K., Lausen B., Schroeder H., Rosthoej S., Carlsen N., Schmiegelow K., Peterson C. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood. 2010;115(23):4671–7. doi:10.1182/blood-2010-01-256958.Gregers J., Christensen I.J., Dalhoff K., Lausen B., Schroeder H., Rosthoej S., Carlsen N., Schmiegelow K., Peterson C. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood. 2010;115(23):4671–7. doi:10.1182/blood-2010-01-256958.Eldem I., Yavuz D., Cumaogullari O., Özge İ., Talia Ü.İ., Elif E.M., Doğanay E., Özdağ H., Şatiroğlu-Tufan N.L., Uysal L. SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy. J Pediatr Hematol Oncol. 2018;40(5):e289–94. doi:10.1097/MPH.0000000000001153.Eldem I., Yavuz D., Cumaogullari O., Özge İ., Talia Ü.İ., Elif E.M., Doğanay E., Özdağ H., Şatiroğlu-Tufan N.L., Uysal L. SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy. J Pediatr Hematol Oncol. 2018;40(5):e289–94. doi:10.1097/MPH.0000000000001153.Marino S., Verzegnassi F., Tamaro P., Stocco G., Bartoli F., Decorti G., Rabusin M. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer. 2009;53(6):984–91. doi:10.1002/pbc.22163.Marino S., Verzegnassi F., Tamaro P., Stocco G., Bartoli F., Decorti G., Rabusin M. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer. 2009;53(6):984–91. doi:10.1002/pbc.22163.Smid A., Karas-Kuzelicki N., Jazbec J. PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep. 2016;6:30244. doi:10.1038/srep30244.Smid A., Karas-Kuzelicki N., Jazbec J. PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep. 2016;6:30244. doi:10.1038/srep30244.Lennard L., Cartwright C.S., Wade R., Vora A. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol. 2015;169(2):228–40. doi:10.1111/bjh.13240.Lennard L., Cartwright C.S., Wade R., Vora A. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol. 2015;169(2):228–40. doi:10.1111/bjh.13240.Milosevic G., Kotur N., Krstovski N., Lazic J., Zukic B., Stankovic B., Janic D., Katsila T., Patrinos G.P., Pavlovic S., Dokmanovic L. Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia. J Med Biochem. 2018;37(3):320–7. doi:10.1515/jomb-2017-0060.Milosevic G., Kotur N., Krstovski N., Lazic J., Zukic B., Stankovic B., Janic D., Katsila T., Patrinos G.P., Pavlovic S., Dokmanovic L. Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia. J Med Biochem. 2018;37(3):320–7. doi:10.1515/jomb-2017-0060.Albayrak M., Konyssova U., Kaya Z., Gursel T., Guntekin S., Percin E.F., Kocak U. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2011;68(5):1155–9. doi:10.1007/s00280-011-1599-7.Albayrak M., Konyssova U., Kaya Z., Gursel T., Guntekin S., Percin E.F., Kocak U. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2011;68(5):1155–9. doi:10.1007/s00280-011-1599-7.Liang D.C., Yang C.P., Liu H.C., Jaing T.H., Chen S.H., Hung I.J., Yeh T.C., Lin T.H., Lai C.L., Lai C.Y., Shih L.Y. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):536–9. doi:10.1038/tpj.2015.75.Liang D.C., Yang C.P., Liu H.C., Jaing T.H., Chen S.H., Hung I.J., Yeh T.C., Lin T.H., Lai C.L., Lai C.Y., Shih L.Y. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):536–9. doi:10.1038/tpj.2015.75.Soler A.M., Olano N., Méndez Y., Lopes A., Silveira A., Dabezies A., Castillo L., da Luz J.A. TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay. Br J Haematol. 2018;181(2):252–5. doi:10.1111/bjh.Soler A.M., Olano N., Méndez Y., Lopes A., Silveira A., Dabezies A., Castillo L., da Luz J.A. TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay. Br J Haematol. 2018;181(2):252–5. doi:10.1111/bjh.Moriyama T., Nishii R., Perez-Andreu V., Yang W., Klussmann F.A., Zhao X., Lin T.N., Hoshitsuki K., Nersting J., Kihira K., Hofmann U., Komada Y., Kato M., McCorkle R., Li L., Koh K., Najera C.R., Kham S.K., Isobe T., Chen Z., Chiew E.K., Bhojwani D., Jeffries C., Lu Y., Schwab M., Inaba H., Pui C.H., Relling M.V., Manabe A., Hori H., Schmiegelow K., Yeoh A.E., Evans W.E., Yang J.J. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–73. doi:10.1038/ng.3508.Moriyama T., Nishii R., Perez-Andreu V., Yang W., Klussmann F.A., Zhao X., Lin T.N., Hoshitsuki K., Nersting J., Kihira K., Hofmann U., Komada Y., Kato M., McCorkle R., Li L., Koh K., Najera C.R., Kham S.K., Isobe T., Chen Z., Chiew E.K., Bhojwani D., Jeffries C., Lu Y., Schwab M., Inaba H., Pui C.H., Relling M.V., Manabe A., Hori H., Schmiegelow K., Yeoh A.E., Evans W.E., Yang J.J. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–73. doi:10.1038/ng.3508.Yang J.J., Landier W., Yang W., Liu C., Hageman L., Cheng C., Pei D., Chen Y., Crews K.R., Kornegay N., Wong F.L., Evans W.E., Pui C.H., Bhatia S., Relling M.V. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235–42. doi:10.1200/JCO.2014.59.4671.Yang J.J., Landier W., Yang W., Liu C., Hageman L., Cheng C., Pei D., Chen Y., Crews K.R., Kornegay N., Wong F.L., Evans W.E., Pui C.H., Bhatia S., Relling M.V. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235–42. doi:10.1200/JCO.2014.59.4671.Zhou H., Li L., Yang P. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer. 2018;18(1):516. doi:10.1186/s12885-018-4398-2.Zhou H., Li L., Yang P. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer. 2018;18(1):516. doi:10.1186/s12885-018-4398-2.Khera S., Trehan A., Bhatia P., Singh M., Bansal D., Varma N. Prevalence of TPMT, ITPA and NUDT15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019;83(2):341–8. doi:10.1007/s00280-018-3732-3.Khera S., Trehan A., Bhatia P., Singh M., Bansal D., Varma N. Prevalence of TPMT, ITPA and NUDT15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019;83(2):341–8. doi:10.1007/s00280-018-3732-3.Moradveisi B., Muwakkit S., Zamani F., Ghaderi E., Mohammadi E., Zgheib N.K. TPMT, ITPA and NUDT15 Genetic Polymorphisms Predict 6-Mercaptopurine Toxicity in Middle Eastern Children With Acute Lymphoblastic Leukemia. Front Pharmacol. 2019;10:916. doi:10.3389/fphar.2019.00916.Moradveisi B., Muwakkit S., Zamani F., Ghaderi E., Mohammadi E., Zgheib N.K. TPMT, ITPA and NUDT15 Genetic Polymorphisms Predict 6-Mercaptopurine Toxicity in Middle Eastern Children With Acute Lymphoblastic Leukemia. Front Pharmacol. 2019;10:916. doi:10.3389/fphar.2019.00916.Huang L., Tissing W.J., de Jonge R., van Zelst B.D., Pieters R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22(9):1798–800. doi:10.1038/leu.2008.66.Huang L., Tissing W.J., de Jonge R., van Zelst B.D., Pieters R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22(9):1798–800. doi:10.1038/leu.2008.66.Chiusolo P., Reddiconto G., Casorelli I., Laurenti L., Sorà F., Mele L., Annino L., Leone G., Sica S. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol. 2002;13(12):1915–8. doi:10.1093/annonc/mdf322.Chiusolo P., Reddiconto G., Casorelli I., Laurenti L., Sorà F., Mele L., Annino L., Leone G., Sica S. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol. 2002;13(12):1915–8. doi:10.1093/annonc/mdf322.Shimasaki N., Mori T., Torii C., Sato R., Shimada H., Tanigawara Y., Kosaki K., Takahashi T. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008;30(5):347–52. doi:10.1097/MPH.0b013e318165b25d.Shimasaki N., Mori T., Torii C., Sato R., Shimada H., Tanigawara Y., Kosaki K., Takahashi T. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008;30(5):347–52. doi:10.1097/MPH.0b013e318165b25d.Kodidela S., Pradhan S.C., Dubashi B., Basu D. Influence of dihydrofolate reductase gene polymorphisms rs408626 (−317A>G) and rs442767 (−680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2015;71(11):1349–58. doi:10.1007/s00228-015-1930-z.Kodidela S., Pradhan S.C., Dubashi B., Basu D. Influence of dihydrofolate reductase gene polymorphisms rs408626 (−317A>G) and rs442767 (−680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2015;71(11):1349–58. doi:10.1007/s00228-015-1930-z.Salazar J., Altés A., del Río E., Estella J., Rives S., Tasso M., Navajas A., Molina J., Villa M., Vivanco J.L., Torrent M., Baiget M., Badell I. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J. 2012;12(5):379–85. doi:10.1038/tpj.2011.25.Salazar J., Altés A., del Río E., Estella J., Rives S., Tasso M., Navajas A., Molina J., Villa M., Vivanco J.L., Torrent M., Baiget M., Badell I. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J. 2012;12(5):379–85. doi:10.1038/tpj.2011.25.Wang Q., He G., Hou M. Cell Cycle Regulation by Alternative Polyadenylation of CCND1. Sci Rep. 2018;8(1):6824. doi:10.1038/s41598-018-25141-0.Wang Q., He G., Hou M. Cell Cycle Regulation by Alternative Polyadenylation of CCND1. Sci Rep. 2018;8(1):6824. doi:10.1038/s41598-018-25141-0.Garcia-Bournissen F., Moghrabi A., Krajinovic M. Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk Res. 2007;31(7):1023–5. doi:10.1016/j.leukres.2006.08.007.Garcia-Bournissen F., Moghrabi A., Krajinovic M. Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk Res. 2007;31(7):1023–5. doi:10.1016/j.leukres.2006.08.007.Oosterom N., Berrevoets M., den Hoed M.A.H., Zolk O., Hoerning S., Pluijm S.M.F, Pieters R., de Jonge R., Tissing W.J.E, van den Heuvel-Eibrink M.M., Heil S.G. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2018;28(10):223–9. doi:10.1097/FPC.0000000000000352.Oosterom N., Berrevoets M., den Hoed M.A.H., Zolk O., Hoerning S., Pluijm S.M.F, Pieters R., de Jonge R., Tissing W.J.E, van den Heuvel-Eibrink M.M., Heil S.G. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2018;28(10):223–9. doi:10.1097/FPC.0000000000000352.Treviño L.R., Shimasaki N., Yang W., Panetta J.C., Cheng C., Pei D., Chan D., Sparreboom A., Giacomini K.M., Pui C.H., Evans W.E., Relling M.V. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972–8. doi:10.1200/JCO.2008.20.4156.Treviño L.R., Shimasaki N., Yang W., Panetta J.C., Cheng C., Pei D., Chan D., Sparreboom A., Giacomini K.M., Pui C.H., Evans W.E., Relling M.V. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972–8. doi:10.1200/JCO.2008.20.4156.Lopez-Lopez E., Ballesteros J., Piñan M.A., Sanchez de Toledo J., Garcia de Andoin N., Garcia-Miguel P., Navajas A., Garcia-Orad A. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2013;23(2):53–61. doi:10.1097/FPC.0b013e32835c3b24.Lopez-Lopez E., Ballesteros J., Piñan M.A., Sanchez de Toledo J., Garcia de Andoin N., Garcia-Miguel P., Navajas A., Garcia-Orad A. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2013;23(2):53–61. doi:10.1097/FPC.0b013e32835c3b24.den Hoed M.A., Lopez-Lopez E., te Winkel M.L., Tissing W., de Rooij J.D., Gutierrez-Camino A., Garcia-Orad A., den Boer E., Pieters R., Pluijm S.M., de Jonge R., van den Heuvel-Eibrink M.M. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(3):248–54. doi:10.1038/tpj.2014.63.den Hoed M.A., Lopez-Lopez E., te Winkel M.L., Tissing W., de Rooij J.D., Gutierrez-Camino A., Garcia-Orad A., den Boer E., Pieters R., Pluijm S.M., de Jonge R., van den Heuvel-Eibrink M.M. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(3):248–54. doi:10.1038/tpj.2014.63.Roy Moulik N., Kumar A., Agrawal S., Awasthi S., Mahdi A.A., Kumar A. Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2015;56(5):1379–84. doi:10.3109/10428194.2014.947608.Roy Moulik N., Kumar A., Agrawal S., Awasthi S., Mahdi A.A., Kumar A. Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2015;56(5):1379–84. doi:10.3109/10428194.2014.947608.Hunger S.P., Loh M.L., Whitlock J.A., Winick N.J., Carroll W.L., Devidas M., Raetz E.A. COG Acute Lymphoblastic Leukemia Committee. Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(6):957–63. doi:10.1002/pbc.24420.Hunger S.P., Loh M.L., Whitlock J.A., Winick N.J., Carroll W.L., Devidas M., Raetz E.A. COG Acute Lymphoblastic Leukemia Committee. Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(6):957–63. doi:10.1002/pbc.24420.Gutierrez-Camino A., Martin-Guerrero I., Garcia-Orad A. PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort. Clin Pharmacol Ther. 2017;102(6):906. doi:10.1002/cpt.756.Gutierrez-Camino A., Martin-Guerrero I., Garcia-Orad A. PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort. Clin Pharmacol Ther. 2017;102(6):906. doi:10.1002/cpt.756.Kienesberger P.C., Oberer M., Lass A., Zechner R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. J Lipid Res. 2009;50(Suppl):S63–8. doi:10.1194/jlr.R800082-JLR200.Kienesberger P.C., Oberer M., Lass A., Zechner R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. J Lipid Res. 2009;50(Suppl):S63–8. doi:10.1194/jlr.R800082-JLR200.He X., Yao P., Li M., Liang H., Liu Y., Du S., Zhang M., Sun W., Wang Z., Hao X., Yu Z., Gao F., Liu X., Tong R. A Risk Scoring Model for High-Dose Methotrexate-Induced Liver Injury in Children With Acute Lymphoblastic Leukemia Based on Gene Polymorphism Study. Front Pharmacol. 2021;12:726229. doi:10.3389/fphar.2021.726229.He X., Yao P., Li M., Liang H., Liu Y., Du S., Zhang M., Sun W., Wang Z., Hao X., Yu Z., Gao F., Liu X., Tong R. A Risk Scoring Model for High-Dose Methotrexate-Induced Liver Injury in Children With Acute Lymphoblastic Leukemia Based on Gene Polymorphism Study. Front Pharmacol. 2021;12:726229. doi:10.3389/fphar.2021.726229.Liu Y., Fernandez C.A., Smith C., Yang W., Cheng C., Panetta J.C., Kornegay N., Liu C., Ramsey L.B., Karol S.E., Janke L.J., Larsen E.C., Winick N., Carroll W.L., Loh M.L., Raetz E.A., Hunger S.P., Devidas M., Yang J.J., Mullighan C.G., Zhang J., Evans W.E., Jeha S., Pui C.H., Relling M.V. Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. Clin Pharmacol Ther. 2017;102(1):131–40. doi:10.1002/cpt.629.Liu Y., Fernandez C.A., Smith C., Yang W., Cheng C., Panetta J.C., Kornegay N., Liu C., Ramsey L.B., Karol S.E., Janke L.J., Larsen E.C., Winick N., Carroll W.L., Loh M.L., Raetz E.A., Hunger S.P., Devidas M., Yang J.J., Mullighan C.G., Zhang J., Evans W.E., Jeha S., Pui C.H., Relling M.V. Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. Clin Pharmacol Ther. 2017;102(1):131–40. doi:10.1002/cpt.629.Ongaro A., De Mattei M., Della Porta M.G., Rigolin G., Ambrosio C., Di Raimondo F., Pellati A., Masieri F.F., Caruso A., Catozzi L., Gemmati D. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009;94(10):1391–8. doi:10.3324/haematol.2009.008326.Ongaro A., De Mattei M., Della Porta M.G., Rigolin G., Ambrosio C., Di Raimondo F., Pellati A., Masieri F.F., Caruso A., Catozzi L., Gemmati D. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009;94(10):1391–8. doi:10.3324/haematol.2009.008326.Tanaka Y., Manabe A., Nakadate H. Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma. 2014;55(5):1126–31. doi:10.3109/10428194.2013.825902.Tanaka Y., Manabe A., Nakadate H. Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma. 2014;55(5):1126–31. doi:10.3109/10428194.2013.825902.Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapyinduced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77. doi:10.1016/j.critrevonc.2011.04.012.Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapyinduced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77. doi:10.1016/j.critrevonc.2011.04.012.Abaji R., Ceppi F., Patel S., Gagné V., Xu C.J., Spinella J.F., Colombini A., Parasole R., Buldini B., Basso G., Conter V., Cazzaniga G., Leclerc J.M., Laverdière C., Sinnett D., Krajinovic M. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identifi ed using whole-exome sequencing. Pharmacogenomics. 2018;19(15):1181–93. doi:10.2217/pgs-2018-0093.Abaji R., Ceppi F., Patel S., Gagné V., Xu C.J., Spinella J.F., Colombini A., Parasole R., Buldini B., Basso G., Conter V., Cazzaniga G., Leclerc J.M., Laverdière C., Sinnett D., Krajinovic M. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identifi ed using whole-exome sequencing. Pharmacogenomics. 2018;19(15):1181–93. doi:10.2217/pgs-2018-0093.Mroß C., Marko M., Munck M., Glöckner G., Motameny S., Altmüller J., Noegel A.A., Eichinger L., Peche V.S., Neumann S. Depletion of Nesprin-2 is associated with an embryonic lethal phenotype in mice. Nucleus. 2018;9(1):503–15. doi:10.1080/19491034.2018.1523664.Mroß C., Marko M., Munck M., Glöckner G., Motameny S., Altmüller J., Noegel A.A., Eichinger L., Peche V.S., Neumann S. Depletion of Nesprin-2 is associated with an embryonic lethal phenotype in mice. Nucleus. 2018;9(1):503–15. doi:10.1080/19491034.2018.1523664.Ceppi F., Langlois-Pelletier C., Gagné V., Rousseau J., Ciolino C., De Lorenzo S., Kevin K.M., Cijov D., Sallan S.E., Silverman L.B., Neuberg D., Kutok J.L., Sinnett D., Laverdière C., Krajinovic M. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(8):1105–16. doi:10.2217/pgs.14.68.Ceppi F., Langlois-Pelletier C., Gagné V., Rousseau J., Ciolino C., De Lorenzo S., Kevin K.M., Cijov D., Sallan S.E., Silverman L.B., Neuberg D., Kutok J.L., Sinnett D., Laverdière C., Krajinovic M. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(8):1105–16. doi:10.2217/pgs.14.68.Lopez-Lopez E., Gutierrez-Camino A., Astigarraga I., Navajas A., Echebarria-Barona A., Garcia-Miguel P., Garcia de Andoin N., Lobo C., Guerra-Merino I., Martin-Guerrero I., Garcia-Orad A. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016;17(7):731–41. doi:10.2217/pgs-2016-0001.Lopez-Lopez E., Gutierrez-Camino A., Astigarraga I., Navajas A., Echebarria-Barona A., Garcia-Miguel P., Garcia de Andoin N., Lobo C., Guerra-Merino I., Martin-Guerrero I., Garcia-Orad A. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016;17(7):731–41. doi:10.2217/pgs-2016-0001.Diouf B., Crews K.R., Lew G., Pei D., Cheng C., Bao J., Zheng J.J., Yang W., Fan Y., Wheeler H.E., Wing C., Delaney S.M., Komatsu M., Paugh S.W., McCorkle J.R., Lu X., Winick N.J., Carroll W.L., Loh M.L., Hunger S.P., Devidas M., Pui C.H., Dolan M.E., Relling M.V., Evans W.E. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815–23. doi:10.1001/jama.2015.0894.Diouf B., Crews K.R., Lew G., Pei D., Cheng C., Bao J., Zheng J.J., Yang W., Fan Y., Wheeler H.E., Wing C., Delaney S.M., Komatsu M., Paugh S.W., McCorkle J.R., Lu X., Winick N.J., Carroll W.L., Loh M.L., Hunger S.P., Devidas M., Pui C.H., Dolan M.E., Relling M.V., Evans W.E. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815–23. doi:10.1001/jama.2015.0894.Zhang J., Fei T., Li Z., Zhu G., Wang L., Chen Y.G. BMP induces cochlin expression to facilitate self-renewal and suppress neural differentiation of mouse embryonic stem cells. J Biol Chem. 2013;288(12):8053–60. doi:10.1074/jbc.M112.433995.Zhang J., Fei T., Li Z., Zhu G., Wang L., Chen Y.G. BMP induces cochlin expression to facilitate self-renewal and suppress neural differentiation of mouse embryonic stem cells. J Biol Chem. 2013;288(12):8053–60. doi:10.1074/jbc.M112.433995.Li L., Sajdyk T., Smith E.M.L., Chang C.W., Li C., Ho R.H., Hutchinson R., Wells E., Skiles J.L., Winick N., Martin P.L., Renbarger J.L. Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2019;105(6):1421–8. doi:10.1002/cpt.1324.Li L., Sajdyk T., Smith E.M.L., Chang C.W., Li C., Ho R.H., Hutchinson R., Wells E., Skiles J.L., Winick N., Martin P.L., Renbarger J.L. Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2019;105(6):1421–8. doi:10.1002/cpt.1324.Bond A.M., Bhalala O.G., Kessler J.A. The dynamic role of bone morphogenetic proteins in neural stem cell fate and maturation. Dev Neurobiol. 2012;72(7):1068–84. doi:10.1002/dneu.22022.Bond A.M., Bhalala O.G., Kessler J.A. The dynamic role of bone morphogenetic proteins in neural stem cell fate and maturation. Dev Neurobiol. 2012;72(7):1068–84. doi:10.1002/dneu.22022.Janke L.J., Liu C., Vogel P., Kawedia J., Boyd K.L., Funk A.J., Relling M.V. Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am J Pathol. 2013;183(1):19–25. doi:10.1016/j.ajpath.2013.03.004.Janke L.J., Liu C., Vogel P., Kawedia J., Boyd K.L., Funk A.J., Relling M.V. Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am J Pathol. 2013;183(1):19–25. doi:10.1016/j.ajpath.2013.03.004.Maurer T., Zimmermann G., Maurer S., Stegmaier S., Wagner C., Hansch G.M. Inhibition of osteoclast generation: a novel function of the bone morphogenetic protein 7/osteogenic protein 1. Mediators Inflamm. 2012;2012:171209. doi:10.1155/2012/171209.Maurer T., Zimmermann G., Maurer S., Stegmaier S., Wagner C., Hansch G.M. Inhibition of osteoclast generation: a novel function of the bone morphogenetic protein 7/osteogenic protein 1. Mediators Inflamm. 2012;2012:171209. doi:10.1155/2012/171209.Zhang S., Fantozzi I., Tigno D.D., Yi E.S., Platoshyn O., Thistlethwaite P.A., Kriett J.M., Yung G., Rubin L.J., Yuan J.X. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003;285(3):L740–54. doi:10.1152/ajplung.00284.200265.Zhang S., Fantozzi I., Tigno D.D., Yi E.S., Platoshyn O., Thistlethwaite P.A., Kriett J.M., Yung G., Rubin L.J., Yuan J.X. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003;285(3):L740–54. doi:10.1152/ajplung.00284.200265.Relling M.V., Yang W., Das S., Cook E.H., Rosner G.L., Neel M., Kaste S.C. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol. 2004;22(19):3930–6. doi:10.1200/JCO.2004.11.020.Relling M.V., Yang W., Das S., Cook E.H., Rosner G.L., Neel M., Kaste S.C. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol. 2004;22(19):3930–6. doi:10.1200/JCO.2004.11.020.Liu C., Yang W., Devidas M., Cheng C., Pei D., Smith C., Carroll W.L., Raetz E.A., Bowman W.P., Larsen E.C., Maloney K.W., Martin P.L., Mattano L.A. Jr, Winick N.J., Mardis E.R., Fulton R.S., Bhojwani D., Howard S.C., Jeha S., Pui C.H., Hunger S.P., Evans W.E., Loh M.L., Relling M.V. Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. J Clin Oncol. 2016;34(18):2133–40. doi:10.1200/JCO.2015.64.5812.Liu C., Yang W., Devidas M., Cheng C., Pei D., Smith C., Carroll W.L., Raetz E.A., Bowman W.P., Larsen E.C., Maloney K.W., Martin P.L., Mattano L.A. Jr, Winick N.J., Mardis E.R., Fulton R.S., Bhojwani D., Howard S.C., Jeha S., Pui C.H., Hunger S.P., Evans W.E., Loh M.L., Relling M.V. Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. J Clin Oncol. 2016;34(18):2133–40. doi:10.1200/JCO.2015.64.5812.Abaji R., Gagné V., Xu C.J., Spinella J.F., Ceppi F., Laverdière C., Leclerc J.M., Sallan S.E., Neuberg D., Kutok J.L., Silverman L.B., Sinnett D., Krajinovic M. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget. 2017;8(27):43752–67. doi:10.18632/oncotarget.17959. PMID:28574850.Abaji R., Gagné V., Xu C.J., Spinella J.F., Ceppi F., Laverdière C., Leclerc J.M., Sallan S.E., Neuberg D., Kutok J.L., Silverman L.B., Sinnett D., Krajinovic M. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget. 2017;8(27):43752–67. doi:10.18632/oncotarget.17959. PMID:28574850.Коркина Ю.С., Валиев Т.Т. L-аспарагиназа: новое об известном препарате. Педиатрическая фармакология. 2021;18(3):227–32. doi:10.15690/pf.v18i3.2282.Korkina Yu.S., Valiev T.T. L-asparaginase: new about well-known drug. Pediatricheskaya farmakologiya = Pediatric Pharmacology. 2021;18(3):227–32. (In Russ.).Fernandez C.A., Stewart E., Panetta J.C., Wilkinson M.R., Morrison A.R., Finkelman F.D., Sandlund J.T., Pui C.H., Jeha S., Relling M.V., Campbell P.K. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol. 2014;73(6):1307–13. doi:10.1007/s00280-014-2464-2.Fernandez C.A., Stewart E., Panetta J.C., Wilkinson M.R., Morrison A.R., Finkelman F.D., Sandlund J.T., Pui C.H., Jeha S., Relling M.V., Campbell P.K. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol. 2014;73(6):1307–13. doi:10.1007/s00280-014-2464-2.Chen S.H., Pei D., Yang W., Cheng C., Jeha S., Cox N.J., Evans W.E., Pui C.H., Relling M.V. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 2010;88(2):191–6. doi:10.1038/clpt.2010.94.Chen S.H., Pei D., Yang W., Cheng C., Jeha S., Cox N.J., Evans W.E., Pui C.H., Relling M.V. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 2010;88(2):191–6. doi:10.1038/clpt.2010.94.Kutszegi N., Yang X., Gézsi A., Schermann G., Erdélyi D.J., Semsei Á.F., Szalai C. HLA-DRB1*07:01-HLA-DQA1*02:01-HLADQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia. Haematologica. 2017;102(9):1578–86. doi:10.3324/haematol.2017.168211.Kutszegi N., Yang X., Gézsi A., Schermann G., Erdélyi D.J., Semsei Á.F., Szalai C. HLA-DRB1*07:01-HLA-DQA1*02:01-HLADQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia. Haematologica. 2017;102(9):1578–86. doi:10.3324/haematol.2017.168211.van der Wouden C.H., Cambon-Thomsen A., Cecchin E., Cheung K.C., Dávila-Fajardo C.L., Deneer V.H., Dolžan V., Ingelman-Sundberg M., Jönsson S., Karlsson M.O., Kriek M., Mitropoulou C., Patrinos G.P., Pirmohamed M., Samwald M., Schaeffeler E., Schwab M., Steinberger D., Stingl J., Sunder-Plassmann G., Toffoli G., Turner R.M., van Rhenen M.H., Swen J.J., Guchelaar H.J. Ubiquitous Pharmacogenomics Consortium. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther. 2017;101(3):341–58. doi:10.1002/cpt.602.van der Wouden C.H., Cambon-Thomsen A., Cecchin E., Cheung K.C., Dávila-Fajardo C.L., Deneer V.H., Dolžan V., Ingelman-Sundberg M., Jönsson S., Karlsson M.O., Kriek M., Mitropoulou C., Patrinos G.P., Pirmohamed M., Samwald M., Schaeffeler E., Schwab M., Steinberger D., Stingl J., Sunder-Plassmann G., Toffoli G., Turner R.M., van Rhenen M.H., Swen J.J., Guchelaar H.J. Ubiquitous Pharmacogenomics Consortium. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther. 2017;101(3):341–58. doi:10.1002/cpt.602.Volpi S., Bult C.J., Chisholm R.L., Deverka P.A., Ginsburg G.S., Jacob H.J., Kasapi M., McLeod H.L., Roden D.M., Williams M.S., Green E.D., Rodriguez L.L., Aronson S., Cavallari L.H., Denny J.C., Dressler L.G., Johnson J.A., Klein T.E., Leeder J.S., Piquette-Miller M., Perera M., Rasmussen-Torvik L.J., Rehm H.L., Ritchie M.D., Skaar T.C., Wagle N., Weinshilboum R., Weitzel K.W., Wildin R., Wilson J., Manolio T.A., Relling M.V. Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clin Pharmacol Ther. 2018;103(5):778–86. doi:10.1002/cpt.1048.Volpi S., Bult C.J., Chisholm R.L., Deverka P.A., Ginsburg G.S., Jacob H.J., Kasapi M., McLeod H.L., Roden D.M., Williams M.S., Green E.D., Rodriguez L.L., Aronson S., Cavallari L.H., Denny J.C., Dressler L.G., Johnson J.A., Klein T.E., Leeder J.S., Piquette-Miller M., Perera M., Rasmussen-Torvik L.J., Rehm H.L., Ritchie M.D., Skaar T.C., Wagle N., Weinshilboum R., Weitzel K.W., Wildin R., Wilson J., Manolio T.A., Relling M.V. Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clin Pharmacol Ther. 2018;103(5):778–86. doi:10.1002/cpt.1048.

The authors declare that there are no conflicts of interest present.